ICICI Prudential NIFTY Pharma Index Fund
Index Sector & Thematic · Direct plan · Growth
₹21.97
+₹0.01 (+0.05%) today
NAV on 20 Nov 2026
Returns
Up to a year
| Period | This fund | NIFTY Pharma |
|---|---|---|
| 1 month | +10.79% | +10.85% |
| 3 months | +7.38% | +7.49% |
| 6 months | +14.44% | +14.69% |
| This year | +25.12% | +25.68% |
| 1 year | +25.25% | +25.88% |
Longer term
| This fund | NIFTY Pharma | NIFTY Pharma | |||
|---|---|---|---|---|---|
| Total | A year | Total | A year | ||
| 2 years | +31.01% | +14.5% | +14.9% | ||
| 3 years | +79.97% | +21.6% | +22.4% | ||
| 5 years | – | – | +16.4% | ||
| 7 years | – | – | +21.0% | ||
| 10 years | – | – | +11.0% | ||
| Since inception | +119.7% | +22.1% | +23.3% | ||
₹1 lakh invested 3 years ago is ₹1.8 lakh today.
From the plan's own NAV, to 20 Nov 2026. Past returns are no guide to the future.
RiskWorst fall -16.6% · volatility 15.6% a year
Volatility, 3 years
15.6%
NIFTY Pharma 15.6%
Worst fall
-16.6%
Feb 2025, back by May 2026
Worst calendar year
-2.6%
2025
Up months
61%
last 3 years
More measures ›Fewer measures ‹
Sharpe ratio, 3 years
0.98
Return above the CRISIL Overnight Index per unit of volatility
Sortino ratio, 3 years
1.90
The same, counting only falls
Alpha vs NIFTY Pharma
-0.67%
Yearly return beyond what its beta explains
Beta vs NIFTY Pharma
1.00
Moves this much when the index moves 1%
Share of the index's rises
99%
In months the index rose
Share of the index's falls
102%
In months the index fell; lower is better
Over the last 3 years, from the fund's NAVs against the NIFTY Pharma.
What stands out
What it holds
21 holdings · as of Aug 2026
- 1Sun Pharmaceutical Industries Ltd20.76%
- 2Divi'S Laboratories Ltd11.88%
- 3Cipla Ltd7.83%
- 4Laurus Labs Ltd7.36%
- 5Torrent Pharmaceuticals Ltd7.34%
- 6Dr. Reddys Laboratories Ltd6.95%
- 7Lupin Ltd5.25%
- 8Aurobindo Pharma Ltd4.69%
- 9Glenmark Pharmaceuticals Ltd3.69%
- 10Alkem Laboratories Ltd3.08%
About ICICI Prudential NIFTY Pharma Index Fund Direct Plan Growth
ICICI Prudential NIFTY Pharma Index Fund Direct Plan Growth is an Index - Sector & Thematic equity fund from ICICI Prudential Asset Management Company Limited, launched on 25 Nov 2022. Its benchmark is the NIFTY Pharma Index. The expense ratio is 0.51% a year. It manages ₹177 crore. The NAV was ₹21.97 on 20 Nov 2026.
Questions about ICICI Prudential NIFTY Pharma Index Fund
What is the NAV of ICICI Prudential NIFTY Pharma Index Fund Direct Growth?
The NAV of ICICI Prudential NIFTY Pharma Index Fund Direct Growth was ₹21.97 on 20 Nov 2026. Mutual fund NAVs are published once a day, after markets close.
What are the returns of ICICI Prudential NIFTY Pharma Index Fund Direct Growth?
ICICI Prudential NIFTY Pharma Index Fund Direct Growth returned 25.3% over 1 year and 21.6% a year over 3 years, to 20 Nov 2026, worked out from its own daily NAV. It returned more than the NIFTY Pharma Index in 2 of 10 calendar years since 2017.
What is the expense ratio of ICICI Prudential NIFTY Pharma Index Fund Direct Growth?
0.51% a year. It is taken from the fund's assets every day, so the NAV and every return shown are already after this cost.
Can NRIs in the UAE invest in ICICI Prudential NIFTY Pharma Index Fund?
NRIs can generally invest once KYC is complete, paying from an NRE or NRO account. ICICI Prudential Mutual Fund accepts investors living in the US only on conditions and does not accept investors living in Canada, per its own documents checked on 15 Nov 2026. Rules change, so confirm with the fund house.
How are ICICI Prudential NIFTY Pharma Index Fund gains taxed for NRIs?
India taxes gains on equity funds at 20% on units held 12 months or less, and at 12.5% on gains above ₹1.25 lakh a year on units held longer, plus cess and any surcharge. For NRIs the tax is deducted when units are redeemed. The UAE has no personal income tax, and the India UAE tax treaty may apply, so confirm your position with a tax adviser.
Rolling returns shows every period, not just the latest.












